


REMARKS

The Examiner is respectfully requested to enter the foregoing amendment prior to examination of the above-identified patent application. In this regard, the present amendment is directed to replacing the originally filed Sequence Listing with the Substitute Sequence Listing filed herewith. Original SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, and 18 listed both nucleotide and amino acid sequences. SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, and 18 have been amended to disclose only nucleotide sequences. The amino acid sequences of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, and 18 are disclosed respectively in original SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, and 17. Original SEQ ID NO: 29 has been removed because it is a duplicate of the nucleotide sequence disclosed in SEQ ID NO: 21. Sequence identifiers have been amended throughout the specification to conform with the Substitute Sequence Listing.

Applicants note that the specification has also been amended to correct typographical mistakes, and to place the sequences in compliance with standard PTO rules and practice. Specifically, the specification has been amended to replace "l" with "n" to represent inosine, or to show that "n" represents A, G, C, or T pursuant to M.P.E.P. §2422. No new matter is added.

If the Examiner has any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted,
Atsushi MIYAWAKI et al.



Bruce H. Bernstein
Reg. No. 29,027

October 12, 2005
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Stephen M. Roylance
Reg. No. 31,296